Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US9233120B2 · kind B2 · utility
1Cited by
39References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2011 |
| Grant date | Jan 12, 2016 |
| Priority date | — |
| Expiry date | May 20, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.